【摘要】 目的:观察尤瑞克林治疗急性脑梗死患者的疗效及安全性。方法:选择急性脑梗死患者106例,随机分成治疗组(56例)和对照组(50例)。对照组患者给予脱水、拜阿司匹林、阿托伐他汀钙片、依达拉奉、丹参多酚酸盐等基础治疗;治疗组患者在对照组基础上加用尤瑞克林治疗。比较两组患者的疗效及安全性。结果:治疗组患者的神经功能缺失评分、残障水平评分均低于对照组;总有效率高于对照组;不良反应发生率为5.4%。结论:在基础治疗的基础上,采用尤瑞克林治疗急性脑梗死患者的疗效优于单纯基础治疗。更多还原

【Abstract】 Objective: To investigate clinical curative effects and safety of Urinary Kallidinogenase in treatment of acute cerebral infarction. Methods: 106 cases of acute cerebral infarction patients were randomly divided into treatment group( n = 56) and control group( n = 50). Both groups were given the basic treatment of dehydration,Aspirin enteric coated tablets,Atorvastatin calcium tablets,Edaravone,Salvianolate and the like; besides,Urinary Kallidinogenase was additionally given to the treatment group. The effects and safety of the two groups were compared. Results: The neurological deficit score and disability level score of treatment group were lower than those of control group; however,the total effective rate was higher than that of control group. The adverse reaction rate of treatment group was 5.4%. Conclusions: Urinary Kallidinogenase based on the basic treatment is more efficacious for acute cerebral infarction than single basic treatment.更多还原